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The Risk of Thromboembolism
and Need for Oral Anticoagulation
After Successful Atrial Fibrillation Ablation
Sakis Themistoclakis, MD,* Andrea Corrado, MD,* Francis E. Marchlinski, MD,† Pierre Jais, MD,‡
Erica Zado, PAC,† Antonio Rossillo, MD,* Luigi Di Biase, MD,§ Robert A. Schweikert, MD,
Walid I. Saliba, MD,¶ Rodney Horton, MD,§ Prasant Mohanty, MBBS, MPH,§ Dimpi Patel, DO,§
David J. Burkhardt, MD,§ Oussama M. Wazni, MD,¶ Aldo Bonso, MD,* David J. Callans, MD,†
Michel Haissaguerre, MD,‡ Antonio Raviele, MD,* Andrea Natale, MD§
Mestre-Venice, Italy; Philadelphia, Pennsylvania; Bordeaux-Pessac, France; Austin, Texas;
and Akron and Cleveland, Ohio
Objectives The aim of this multicenter study was to evaluate the safety of discontinuing oral anticoagulation therapy (OAT)
after apparently successful pulmonary vein isolation.
Background Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events (TE) and often requires OAT.
Pulmonary vein isolation is considered an effective treatment for AF.
Methods We studied 3,355 patients, of whom 2,692 (79% male, mean age 57  11 years) discontinued OAT 3 to 6
months after ablation (Off-OAT group) and 663 (70% male, mean age 59  11 years) remained on OAT after
this period (On-OAT group). CHADS2 (congestive heart failure, hypertension, age [75 years and older], diabetes melli-
tus, and a history of stroke or transient ischemic attack) risk scores of 1 and 2 were recorded in 723 (27%) and
347 (13%) Off-OAT group patients and in 261 (39%) and 247 (37%) On-OAT group patients, respectively.
Results During follow-up (mean 28  13 months vs. 24  15 months), 2 (0.07%) Off-OAT group patients and 3 (0.45%)
On-OAT group patients had an ischemic stroke (p  0.06). No other thromboembolic events occurred. No Off-
OAT group patient with a CHADS2 risk score of 2 had an ischemic stroke. A major hemorrhage was observed
in 1 (0.04%) Off-OAT group patient and 13 (2%) On-OAT group patients (p  0.0001).
Conclusions In this nonrandomized study, the risk–benefit ratio favored the suspension of OAT after successful AF ablation
even in patients at moderate-high risk of TE. This conclusion needs to be confirmed by future large randomized
trials. (J Am Coll Cardiol 2010;55:735–43) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.039s
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atrial fibrillation (AF) is a major risk factor for thrombo-
mbolism, and oral anticoagulation therapy (OAT) is usu-
lly recommended for patients at higher risk of this com-
lication (1,2). Catheter ablation has emerged as a
romising cure for AF (3,4). Reported success rates range
rom 45% to 95% (3). One of the potential advantages of
F ablation is the possibility of discontinuing OAT after a
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wo recent expert consensus documents recommended
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(TE) (3,4). Despite these re-
cent recommendations, the use
of OAT after an apparently
successful ablation procedure is
still controversial, and some
centers implement a policy of
withdrawing OAT even in the
majority of patients at high risk
of TE (17% of 42 centers
worldwide surveyed in a recent
questionnaire) (5). To clarify
this issue, we conducted the
present study by collecting data
from 5 high-volume centers
that have, over the years, imple-
mented a consistent strategy
with regard to the suspension of
OAT after successful ablation.
ethods
atient population. Consecutive patients referred to the 5
articipating centers between January 2001 and December
005 who had discontinued OAT after successful AF
blation were enrolled in the study (Off-OAT group) and
ere compared with patients who had undergone AF
blation in the period January 2003 to December 2005 and
ontinued OAT (On-OAT group). Patients with prosthetic
alves were excluded from the study. On referral, all patient
ata were prospectively recorded in a computerized data-
ase. Both Off- and On-OAT groups were divided into 3
ubgroups according to their TE risk profile. Patients’ risk
rofiles were evaluated by means of the CHADS2 (conges-
ive heart failure, hypertension, age [75 years or older],
iabetes mellitus, history of stroke or transient ischemic
ttack) score. This index is based on a points system in
hich 2 points are assigned for a history of TIA or stroke
nd 1 point for each of the other risk factors. A CHADS2
core of 0 is considered to indicate a low risk of TE, a score
f 1 indicates a moderate risk, and a score of 2 or more
ndicates a high risk (6).
All patients selected for pulmonary vein isolation had a
istory of symptomatic drug-resistant paroxysmal, persis-
ent, or permanent AF (1). A follow-up of at least 1 year
fter the last ablation and 6 months after OAT discontin-
ation was required for inclusion in the study. Before the
blation procedure, all patients gave their written informed
onsent as approved by the institutional ethics committee,
nd patient data were collected in accordance with institu-
ional ethics guidelines.
blation strategy. The ablation strategy included pulmo-
ary vein isolation at the ostial or antral level, guided by a
ircular mapping catheter. Intracardiac echocardiography or
ngiography was used to locate the pulmonary veins and
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
ECG  electrocardiogram
HR  hazard ratio
INR  international
normalized ratio of
prothrombin time
LA  left atrial/atrium
OAT  oral anticoagulation
therapy
TE  thromboembolic
events
TIA  transient ischemic
attack
TTM  transtelephonic
monitoringefine the ostium or the antrum of the veins. Additional tinear lesions, ablation of complex fractionated electro-
rams, and isolation of the superior vena cava were per-
ormed per institutional preference. The details of the
blation procedures have been presented elsewhere (7–9).
nticoagulation protocol. All patients were monitored
vernight in the hospital, and were usually discharged from
to 3 days after the procedure depending on institutional
olicy. The OAT with adjusted-dose warfarin was restarted
n all patients on the evening of the ablation procedure and
ontinued for at least 3 to 6 months to maintain the
nternational normalized ratio of prothrombin time (INR)
etween 2 and 3 (10). After this period, each center decided
he long-term anticoagulation strategy according to local
nstitutional policy and the individual characteristics of each
atient. As a general rule, OAT was discontinued, regard-
ess of the CHADS2 score, if patients did not experience:
) any recurrence of atrial tachyarrhythmias (AF or atrial
utter/tachycardia longer than 1 min); 2) severe pulmonary
ein stenosis (pulmonary vein narrowing 70%); and
) severe left atrial (LA) mechanical dysfunction (absence of
-wave on pulsed Doppler transmitral recording). Patients
ith early recurrence of AF or episodes of atrial flutter and
CHADS2 score of 1 or more were maintained on OAT
or at least 6 months; subsequently, OAT was discontinued
n patients without arrhythmic recurrence in the last 3
onths off antiarrhythmic drugs. After OAT discontinua-
ion, patients were treated with aspirin, 81 to 325 mg/day.
atients with a CHADS2 score of 1 or more who developed
recurrence of atrial tachyarrhythmia after discontinuation
ere restarted on OAT. For the purpose of the present
tudy, the data collected up to the time when these patients
estarted OAT were included in the analysis.
ost-ablation management and follow-up. Follow-up ex-
minations were routinely scheduled at 1 to 3, 6, and 12
onths after the procedure and every 6 months thereafter.
eventy-nine percent of patients were seen up to the 1-year
ollow-up by the physician in the center where the ablation
as performed. For all patients who were unable to be seen
n the first year and thereafter, their status was assessed by
nurse practitioner via telephone and monitoring tests were
btained by the referring physician. In any case, all data
ollected in this way were also evaluated by the physician of
he center where the ablation procedure had been per-
ormed. An electrocardiogram (ECG) was obtained rou-
inely in all patients within 1 month after the procedure and
t each follow-up examination. Each study institution had
ifferent strategies for identifying AF recurrences prior to
AT discontinuation. These included Holter recordings (at
, 3, and 6 months) in 86% of patients and/or transtele-
honic monitoring (TTM) (ranging from continuous for 5
onths in 76% of patients to 1-month blocks immediately
fter, at 6 to 12 weeks, and at 6 months after AF ablation in
4%) in 90% of patients. Patients who underwent TTM
ere asked to transmit their rhythm data every time they
ad symptoms compatible with arrhythmias, and 1 to 3
imes per day even if they were asymptomatic. Interrogation
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February 23, 2010:735–43 Post-AF Ablation Oral Anticoagulationf implanted devices was also used (when available) to
onfirm arrhythmia recurrence. Patients were also instructed
o assess their pulse daily and report any irregularity of pulse
r recurrence of symptoms immediately, at which point
dditional Holter monitoring or TTM was performed. The
ocumentation of arrhythmic episodes was based on ECG
nd/or Holter, TTM, and implanted device recordings.
Transthoracic or transesophageal echocardiography and
piral computed tomography scan were performed during
he 3-month follow-up examination for the assessment of
A function and pulmonary vein narrowing. Complete
dherence to the follow-up protocol was a necessary condi-
ion for the evaluation of OAT discontinuation.
nd points of the study. For the purpose of the study, the
ollowing events were considered as study end points:
schemic strokes and major hemorrhages. Ischemic stroke
as defined as the abrupt onset of focal neurological deficit
ersisting for more than 24 h (11). Major hemorrhage was
efined as bleeding that was intracranial or retroperitoneal,
r led directly to death, or resulted in hospitalization or
ransfusion (12). Patients were enrolled in the study at the
ime when the decision regarding long-term post-ablation
AT was made, and the follow-up started from that
oment. The TE and hemorrhagic events that occurred
hile on OAT, during the initial 3 to 6 months after
blation, were not counted.
tatistical analysis. All data are reported as mean  SD
or continuous variables and as percentage values for cate-
orical variables, unless otherwise indicated. Comparison of
ontinuous variables between 2 groups was made by means
f the independent-samples Student t test. Categorical
ariables were compared by means of chi-square analysis or
isher exact test when required. A 2-tailed p value 0.05
as considered statistically significant. Freedom from isch-
mic and hemorrhagic stroke in the Off- and On-OAT
roups were estimated with Kaplan-Meier analysis and was
ompared by the log-rank test. Hazard ratio (HR) and
elative risk from Cox regression model were used to test the
ffect of OAT discontinuation on the risk of TE and major
emorrhages when more than 10 events were detected. This
odel was adjusted for age, sex, and CHADS2 score.
esults
aseline characteristics and thromboembolic risk. The
ff-OAT group consisted of 2,692 patients who discontin-
ed OAT 5  3 months (median 4 months) after AF
blation. Thereafter, these patients remained off OAT for
nother 28  13 months (median 25 months). Of these
atients, 95 continued antiarrhythmic drug therapy despite the
act that they had no arrhythmic recurrences after the blanking
eriod (first 3 months after ablation). The follow-up duration
as only the minimum required for the enrollment in the study
or 145 (5%) patients. In 2,477 (92%) patients, OAT was
eplaced with aspirin. In the other 215 (8%) patients, aspirin
as not administered because of contraindication, intoler- once, or patient refusal. Among the 2,692 patients in the
ff-OAT group, 1,622 (60%) had a CHADS2 score of 0,
23 (27%) had a CHADS2 score of 1, and 347 (13%) had
CHADS2 score of2. The On-OAT group was made up
f 663 patients who continued OAT for 24  15 months
median 19 months) after the decision not to suspend this
herapy. The reasons for continuing OAT were arrhythmic
ecurrences (n 475, 72%), LA dysfunction (n 66, 10%),
evere pulmonary vein stenosis (n  22, 3%), other indica-
ion for OAT (n  19, 3%), and the decision of the
eferring physician or patient preference (n  81 patients,
2%). Among the 663 patients in the On-OAT group, 155
23%) had a CHADS2 score of 0, 261 (39%) had a
HADS2 score of 1, and 247 (37%) had a CHADS2 score
f2. All patients received transthoracic or transesophageal
chocardiography before the decision regarding long-term
AT was made. Ninety-eight percent of patients fulfilled
he institutional monitoring protocol to assess for arrhyth-
ic recurrences. The baseline characteristics of the whole
tudy population, the Off-OAT group, and On-OAT
roup are summarized in Table 1. Patients in the Off-OAT
roup were more frequently male and were significantly
ounger than patients in the On-OAT group, more often
ad paroxysmal AF, and had a longer duration of AF, a
ower mean CHADS2 score, and a smaller LA diameter.
hese patients were more frequently without structural heart
isease and with left ventricular ejection fraction 40%. In
able 2, patients in the Off- and On-OAT groups are further
ubdivided into 3 subgroups according to the CHADS2 score.
he mean duration of the follow-up did not differ significantly
etween the 2 groups for patients with CHADS2 score 0, 1,
nd2. The distribution of the various risk factors included in
he CHADS2 score for patients of both groups is reported in
able 3. After discussion with patients, OAT also was discon-
inued in 10 subjects with CHADS2 scores of 5 to 6. All of
hese patients had a prior history of stroke or TIA associated
ith other TE risk factors. The OAT was discontinued only if
he previous stroke or TIA was clearly related to AF and all
ules for OAT withdrawal previously mentioned were satisfied.
rrhythmic recurrences during follow-up. In the Off-
AT group, 77 of 2,692 patients (2.9%, 9 patients with
HADS2 score 2) had arrhythmic recurrences 10  3
onths after OAT discontinuation and restarted OAT.
Es during follow-up. In the Off-OAT group, only 2 of
,692 (0.07%) patients experienced ischemic stroke during
ollow-up. These patients survived the TE, and only 1
uffered permanent functional disability. One patient was a
7-year-old man with a CHADS2 risk score of 0 and a
istory of paroxysmal AF before ablation. The event oc-
urred 6 months after OAT discontinuation while the
atient was in sinus rhythm. No arrhythmic recurrences
ere documented before the event. After the stroke, repeat
onitoring revealed both asymptomatic and symptomatic
pisodes of paroxysmal AF. The second patient was a
5-year-old man with a CHADS2 score of 1 and a history
f persistent AF before ablation. The ischemic event oc-
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Post-AF Ablation Oral Anticoagulation February 23, 2010:735–43urred 4 months after OAT discontinuation. Aspirin had
een suspended in this patient 1 month before the event.
epeat monitoring with 24-h Holter recording and TTM
erformed for 1 month after the stroke was not able to
ocument any arrhythmic recurrence. Interestingly, no pa-
ient with a CHADS2 risk score 2 developed TE after
AT discontinuation (Table 4).
In the On-OAT group, the incidence of ischemic stroke
as 0.45% (3 of 663 patients), which did not differ signif-
cantly from that of the Off-OAT group (p  0.06). The
trokes were not fatal. Residual neurological deficits were
bserved in 2 of these patients. One patient was a 78-year-
ld woman with a CHADS2 score of 1 and a history of
ermanent AF. Ablation was not successful, and she re-
ained on OAT after the procedure. The ischemic stroke
ccurred after 9 months of follow-up. The INR at the time
f the event was 1.8. The second patient was a 77-year-old
oman with a history of persistent AF and a CHADS2
core of 2 because of her age and hypertension. She had AF
ecurrences both during and after the 3-month blanking
eriod. One month after the decision to continue OAT, the
Baseline Characteristics of the Total PopulationTable 1 Baseline Characteristics of the Tota
Total Population
(n  3,355)
Sex
Male 2,579 (77)
Female 776 (23)
Age, yrs 57 11
AF type
Paroxysmal 2,022 (60)
Persistent 598 (18)
Permanent 735 (22)
AF duration, months 43 40
Structural heart disease 983 (29)
Valvular 405 (12)
Ischemic 314 (9)
Dilated 149 (4)
Hypertrophic 45 (1)
Others 70 (2)
Thromboembolic risk factors
Congestive heart failure 266 (8)
Hypertension 1,292 (39)
Age 75 yrs 140 (4)
Diabetes 227 (7)
Prior stroke/TIA 230 (7)
CHADS2 score
0 1,777 (53)
1 984 (29)
2 594 (18)
LVEF, % 55 8
LVEF 40%, 254 (8)
LA diameter, mm 44 6
LA diameter 40 mm 2,361 (70)
Values are n (%) and continuous variables are given as mean  SD.
AF  atrial fibrillation; LA  left atrial/atrium; LVEF  left ventric
ischemic attack.atient underwent successful transesophageal echocardio- sraphy–guided cardioversion while on therapeutic INR.
our days later she presented in AF with aphasia and
emiplegia. Ischemic stroke was documented, and the INR
alue was 2.0. The third patient was a 75-year-old man with
history of hypertension and a CHADS2 score of 2. He
nderwent unsuccessful AF ablation, and 4 months after the
ecision to continue OAT developed mono-ocular partial
lindness with documentation of ischemic stroke. The INR
alue at time of the event was 2.2.
emorrhagic events during follow-up. In the Off-OAT
roup, only 1 of 2,692 (0.04%) patients had a major
emorrhage; this patient suffered retroperitoneal bleeding 8
onths after OAT discontinuation.
In the On-OAT group, 13 of 663 (2%) patients had a major
emorrhage (p 0.0001 compared with the Off-OAT group).
wo (0.30%) patients had intracranial hemorrhage, and 11
1.7%) had gastrointestinal bleeding. The hemorrhagic strokes
ccurred 1 and 6 months after the decision to continue OAT,
espectively. The event was fatal in 1 patient and required
urgical evacuation in the other. The INR at the time of the
pisode was not available in the first case and was 2.0 in the
OAT Group, and On-OAT Grouppulation, Off-OAT Group, and On-OAT Group
Off-OAT Group
(n  2,692)
On-OAT Group
(n  663) p Value
2,116 (79) 463 (70) 0.0026
576 (21) 200 (30)
57 11 59 11 0.0001
1,682 (62) 340 (51) 0.0001
424 (16) 174 (26) 0.0001
586 (22) 149 (22) 0.6941
44 36 35 58 0.0019
730 (27) 253 (38) 0.0001
323 (12) 82 (12) 0.7936
242 (9) 72 (11) 0.1386
90 (3) 59 (9) 0.0001
27 (1) 18 (3) 0.006
48 (2) 22 (3) 0.0132
154 (6) 112 (17) 0.0001
916 (34) 376 (57) 0.0001
93 (3) 47 (7) 0.0001
143 (5) 84 (13) 0.0001
125 (5) 105 (16) 0.0001
1,622 (60) 155 (23) 0.0001
723 (27) 261 (39) 0.0001
347 (13) 247 (37) 0.0001
55 8 55 10 0.6590
188 (7) 66 (10) 0.0096
43 6 45 7 0.0001
1,857 (69) 504 (76) 0.0004
ction fraction; OAT  oral anticoagulation therapy; TIA  transient, Off-l Poecond. The gastrointestinal hemorrhages occurred 11  6
Baseline Characteristics of the Whole Study Population, Off-OAT Group, and On-OAT Group According to CHADS2 ScoreTable 2 Baseline Characteristics of the Whole Study Population, Off-OAT Group, and On-OAT Group According to CHADS2 Score
Total Population Off-OAT Group On-OAT Group p Value
CHADS2  0 CHADS2  1 CHADS2 >2 CHADS2  0 CHADS2  1 CHADS2 >2 CHADS2  0 CHADS2  1 CHADS2 >2 CHADS2  0 CHADS2  1 CHADS2 >2
Patients, n 1,777 984 594 1,622 723 347 155 261 247 — — —
Sex
Male 1,410 (79) 770 (78) 399 (67) 1,299 (80) 575 (80) 242 (70) 111 (72) 195 (75) 157 (64) 0.013 0.106 0.114
Female 367 (21) 214 (22) 195 (33) 323 (20) 148 (20) 105 (30) 44 (28) 66 (25) 90 (36)
Age, yrs 54 11 59 9 62 11 54 11 59 9 63 11 55 11 60 9 60 12 0.110 0.467 0.004
AF type
Paroxysmal 1,141 (64) 531 (54) 350 (59) 1,064 (65) 407 (56) 211 (61) 77 (50) 124 (47) 139 (56) 0.001 0.029 0.044
Persistent 243 (14) 241 (24) 114 (19) 206 (13) 163 (23) 55 (16) 37 (24) 78 (30) 59 (24)
Permanent 393 (22) 212 (22) 130 (22) 352 (22) 153 (21) 81 (23) 41 (26) 59 (23) 49 (20)
AF duration, months 42 33 48 50 40 42 42 31 49 45 44 38 35 52 42 72 41 47 0.057 0.387 0.044
SHD 454 (26) 265 (27) 264 (44) 422 (26) 159 (22) 149 (43) 32 (21) 106 (41) 115 (47) 0.143 0.001 0.382
SHD type
Valvular 247 (14) 98 (10) 60 (10) 233 (14) 65 (9) 25 (7) 14 (9) 33 (14) 35 (14) 0.001 0.074 0.001
Ischemic 95 (5) 91 (9) 128 (21) 91 (6) 61 (8) 90 (26) 4 (3) 30 (11) 38 (15)
Dilated 46 (3) 46 (5) 57 (10) 44 (3) 18 (3) 28 (8) 2 (1) 28 (11) 29 (12)
Hypertrophic 22 (1) 16 (2) 7 (1) 17 (1) 7 (1) 3 (1) 5 (3) 9 (3) 4 (2)
Others 44 (3) 14 (1) 12 (2) 37 (2) 8 (1) 3 (1) 7 (5) 6 (2) 9 (4)
LVEF, % 56 6 56 8 50 12 56 6 56 8 48 12 57 7 56 9 53 12 0.089 0.678 0.001
LVEF 40% 44 (2) 53 (5) 157 (26) 40 (2) 35 (5) 113 (33) 4 (3) 18 (7) 44 (18) 0.790 0.056 0.001
LA diameter, mm 43 7 44 6 45 6 42 7 44 6 45 6 44 7 46 7 44 7 0.007 0.001 0.387
LA diameter 40 mm 1,171 (66) 748 (76) 442 (74) 1,059 (65) 537 (74) 261 (75) 112 (72) 211 (81) 181 (73) 0.080 0.033 0.594
OAT discontinuation
after ablation,
months
4 2 5 2 6 3 4 2 5 2 6 3 — — —
Follow-up after OAT
discontinuation,
months
28 16 25 15 28 16 29 16 25 17 29 16 28 9 26 16 27 16 0.402 0.920 0.406
Values are n (%) or mean  SD.
SHD  structural heart disease; other abbreviations as in Table 1.
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Post-AF Ablation Oral Anticoagulation February 23, 2010:735–43onths after the decision to continue OAT (range 4 to 9
onths). All patients were hospitalized; of these, 9 required
lood transfusion and 1 required surgery. The INR at the time
f bleeding was above the normal range in 8 patients (between
.3 and 7.6) and was unavailable in 3. One patient with
navailable INR at the time of the event had gastrointestinal
leeding due to gastric ulcers while on treatment with OAT
nd nonsteroidal anti-inflammatory agents. No patient died of
hese events.
omparison of event-free survival between the Off- and
n-OAT group. The annual ischemic stroke rate per 100
atient-years was 0.03 (95% confidence interval [CI]: 0.004
o 0.114) in the Off-OAT group and 0.23 (95% CI: 0.047
o 0.662) in the On-OAT group (p  0.049). The annual
ate for overall thromboembolic and hemorrhagic strokes
er 100 patient-years was 0.03 (95% CI: 0.004 to 0.114) for
he Off-OAT group and 0.38 (95% CI: 0.123 to 0.881) for
he On-OAT group (p  0.002). Major hemorrhages were
ignificantly more frequent in the On-OAT group, with an
nnual rate per 100 patient-years of 0.98 (95% CI: 0.523 to
.678) compared with 0.02 (95% CI: 0.001 to 0.088) in the
ff-OAT group (p  0.0001). The event-free survival
stimates for freedom from ischemic and hemorrhagic
trokes are reported in Figure 1.
In our population, HR for OAT discontinuation indi-
ates that On-OAT group patients experienced major
emorrhage events at a rate that was about 13 times higher
hromboembolic Risk Factors According to CHADS2 Score in the OTable 3 Thromboembolic Risk Factors According to CHADS2 Sc
0 1 2
Off-OAT group, n
Congestive HF 0 40 70
Hypertension 0 644 175
Age 75 yrs 0 22 43
Diabetes mellitus 0 17 76
Prior stroke/TIA 0 0 63
Total 1,622 723 245
On-OAT group, n
Congestive HF 0 37 51
Hypertension 0 211 113
Age 75 yrs 0 6 29
Diabetes mellitus 0 7 53
Prior stroke/TIA 0 0 68
Total 155 261 191
F  heart failure; other abbreviations as in Table 1.
ncidence of Thromboembolic Events and Major Hemorrhage AccorTable 4 Incidence of Thromboembolic Events and Major Hemor
CHADS2  0
Off-OAT On-OAT
Patients, n 1,622 155
TE, n (%) 1 (0.06) 0
Major hemorrhage, n (%) 0 1 (0.64)AT  oral anticoagulation; TE  thromboembolic events.han that of patients in the Off-OAT group (HR: 12.9, 95%
I: 2.7 to 61.9, p  0.001). Similarly, the overall hemor-
hagic and TEs occurred in the On-OAT group at a rate
hat was about 9 times higher than that in the Off-OAT
roup (HR: 8.9, 95% CI: 2.7 to 28.5, p  0.0002).
iscussion
ain findings. The present study shows that OAT can
afely be discontinued 3 to 6 months after successful
blation of AF in patients without arrhythmic recurrences
ff antiarrhythmic drugs, without severe pulmonary vein
tenosis, and without severe LA dysfunction. Indeed, the
ercentage of TE in patients who suspended OAT after
uccessful ablation of AF was not significantly different from
hat observed in patients who continued OAT after the
rocedure. In patients with CHADS2 scores of 0, 1, and
2, the incidence of TE was 0.06%, 0.14%, and 0%,
espectively, in the Off-OAT group and 0%, 0.38%, and
.81%, respectively, in the On-OAT group. Moreover, the
ncidence of major hemorrhages was significantly lower
mong patients who suspended OAT than among those
ho continued (p  0.0001). In our study, therefore, the
isk–benefit ratio favored the discontinuation of OAT even
n patients with a medium-high TE risk (CHADS2 scores
and 2). Our results suggest that the CHADS2 score
ystem probably is not the most appropriate system for
d On-OAT Groupsin the Off- and On-OAT Groups
DS2 Score
Total3 4 5 6
26 8 8 2 154
72 15 8 2 916
19 5 2 2 93
32 10 6 2 143
41 11 8 2 125
77 15 8 2
15 6 3 0 112
39 9 4 0 376
5 5 2 0 47
15 6 3 0 84
26 7 4 0 105
42 10 4 0
to CHADS2 Score in Off- and On-OAT GroupsAccording to CHADS2 Score in Off- and On-OAT Groups
CHADS2  1 CHADS2 >2
Off-OAT On-OAT Off-OAT On-OAT
723 261 347 247
1 (0.14) 1 (0.38) 0 2 (0.81)
1 (0.14) 2 (0.8) 0 10 (4)ff- anore
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February 23, 2010:735–43 Post-AF Ablation Oral Anticoagulationssessing TE risk and establishing an anticoagulation strat-
gy after AF ablation.
omparison with previous studies. As far as we know,
his is the largest set of case records compiled on patients
ho have undergone long-term suspension of OAT, in
erms of both the total number of patients (n  2,692) and
he number of moderate-/high-risk patients (723 patients
ith CHADS2 score 1 and 347 patients with CHADS2
core 2), in whom OAT is recommended or suggested by
he international guidelines (1,2). Our results are substan-
ially in line with those of other recently published retro-
pective studies involving smaller populations and shorter
ollow-up periods (13–16). In particular, they are similar to
hose observed by Nademanee et al. (14). In a study on
ong-term outcomes after AF substrate ablation guided by
omplex fractionated atrial electrograms, these investigators
ompared the incidence of TE and hemorrhages between
34 patients without arrhythmic recurrences who discon-
inued OAT and 118 patients requiring OAT after unsuc-
essful ablation. These patients were selected from a cohort
f patients who were at least 65 years old or had 1 or more
isk factors for stroke, including hypertension, diabetes,
tructural heart disease, prior history of stroke/TIA, con-
estive heart failure, or left ventricular ejection fraction
40%. In their population, the annual stroke rate was
ignificantly lower in successfully treated patients who
iscontinued OAT than in patients with AF recurrences
ho remained on OAT (0.4% vs. 2%). However, in that
tudy, stroke risk stratification was not based on the
HADS2 score index, nor did the investigators specify the
ercentage of patients with CHADS2 score 2, which
Figure 1 Kaplan-Meier Event-Free Survival Estimates for Freedo
Post-Ablation Thromboembolic and Hemorrhagic Strok
Data have been truncated at 5 years. OAT  oral anticoagulation therapy.dentifies the group of patients at highest risk. dypothesis for the low incidence of TE. In our study, the
ercentage of TE observed in patients who had undergone
uccessful ablation was decidedly low. Various explanations
an be hypothesized for this finding. 1) In our population,
AT was discontinued essentially in patients who suffered
o AF recurrences in the absence of antiarrhythmic drugs
nd after thorough, prolonged monitoring for possible
symptomatic recurrences. 2) All of our patients underwent
re-ablation transesophageal echocardiography, which ex-
luded the presence of endocavitary thrombi, and, before
AT suspension, transthoracic or transesophageal echocar-
iography, which demonstrated the absence of significant
A dysfunction. 3) Patients with other causes of thrombo-
mbolic risk continued OAT. 4) Aspirin was administered
ndefinitely to most of our patients after OAT suspension.
) Finally, our patients restarted OAT systematically and
romptly after any arrhythmic recurrences.
ros and cons of OAT after successful AF ablation. The
easons for continuing anticoagulation after ablation mainly
tem from studies on drug therapy and chiefly concern the
isk of asymptomatic recurrences (1,4). The data in the
iterature indicate that the percentage of patients who suffer
xclusively asymptomatic recurrences after successful AF
blation ranges from 0% to 20% (17,18). These percentages
re decidedly lower than those observed both in patients on
ntiarrhythmic therapy for the prevention of AF recurrences
19) and in patients with permanent pacemakers who have
o history of atrial tachyarrhythmias (20) (70% and 46%,
espectively). Moreover, after successful ablation, asymp-
omatic AF episodes are often short-lived. Indeed, in one
tudy of patients with permanent pacemakers, the maximum
om
the Off- and On-OAT Groupsm Fr
es inuration of asymptomatic atrial tachyarrhythmias was 18 
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rrhythmia (symptomatic and asymptomatic) duration dur-
ng continuous 7-day ECG monitoring was 17 and 10 h, 6
nd 12 months after ablation, respectively (22). Such short-
asting episodes seem to have little clinical significance.
ndeed, according to the observations made by Capucci et
l. (23), the thromboembolic risk increases only in patients
n whom the duration of device-detected AF is 24 h or
ore.
It is important to consider that OAT involves a 1.2% per
ear risk of major hemorrhage (1). The decision to admin-
ster this therapy must therefore be based on a thorough
ssessment of the risk–benefit ratio. Patients with a throm-
oembolic risk of 2% per year or less do not benefit
ubstantially from OAT, and according to the international
uidelines should not be treated with this therapy (1). All of
he studies, included ours, conducted to date on patients
ho have undergone successful AF ablation report a decid-
dly lower incidence of TE than that required by the
uidelines (13–16). Another reason for administering OAT
fter AF ablation is that extensive LA lesions might impair
A function, as observed by Lemola et al. (24) on perform-
ng LA circumferential ablation in patients with paroxysmal
F. However, to the best of our knowledge, no other
tudies have confirmed these data. On the contrary, all of
he other studies on this issue have shown significant
estoration of LA function and a reduction in LA diameters
25–30). In addition, Sacher et al. (29) also found a
estoration of endocrine cardiac function within 3 months in
lmost all patients despite extensive atrial ablation. The
mprovement in LA mechanical function is probably the
esult of inverse electroanatomic remodeling after the res-
oration and maintenance of sinus rhythm.
tudy limitations. This was not a randomized prospective
tudy, but rather a summary of a 5-center experience in
hich similar guidelines for OAT discontinuation were
ollowed. To date, however, it is the observational study
ith the largest set of case records. The design of the study
as retrospective; however, the patients’ data were recorded
rospectively in a computerized database. Future random-
zed studies involving a large population of patients at high
hromboembolic risk (over 3,000 patients) will be necessary
o confirm these data (3).
Another limitation of our study is the relatively scarce
istribution of stroke events in the population. Moreover,
ur On-OAT group was smaller than our Off-OAT group,
nd included patients who underwent ablation in a shorter
eriod of time (3 years vs. 5 years). Nevertheless, the
umber of events, particularly hemorrhagic events, was
istinctly greater. For the difference existing between the 2
roups, covariate analyses were either not possible or had
he risk of overfitting.
It is also important to note that data regarding being in
herapeutic range over time were not systematically col-
ected in the database. We recorded the INR at the time of
he event in all patients who experienced strokes and in theajority of those who experienced hemorrhagic events.
herefore, we cannot exclude the possibility that in these
atients previous INR values were outside of the range or
hat the time in the therapeutic range was not optimal.
After the initial 5 to 6 months post-ablation, TTM was
ot performed systematically. Therefore, we cannot rule out
he possibility that patients may have had asymptomatic
trial tachyarrhythmias after this period. However, periodic
linical and ECG examinations and frequent Holter mon-
toring did not document asymptomatic recurrence and
aily pulse control did not detect irregularities suggestive of
F. Moreover, prolonging a scrupulous TTM further
ould not be feasible in clinical practice, nor would it be
eadily accepted by patients. In any case, the stroke rate in
ur patients who maintained sinus rhythm was very low,
uggesting that if any asymptomatic AF episode occurred, it
as without consequence.
onclusions
e found that patients who discontinued OAT 3 to 6
onths after successful AF ablation had a similar incidence
f TE to patients who remained on OAT. Moreover, the
ate of major hemorrhages was significantly lower. On the
asis of these results, it seems that the risk–benefit ratio
avors the discontinuation of OAT after successful AF
blation even in patients at moderate-high risk of TE based
n CHADS2 score alone. However, this conclusion needs
o be confirmed by future large prospective randomized
rials.
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